In vivo programming of dual-targeted CAR-T cells facilitates vascular disruption and T-cell infiltration in solid tumors
Year: 2026
Type: article
Abstract: T-cell therapies for solid tumors are restricted by abnormal tumor vasculature, which creates structural and immunological barriers to infiltration. Here we report a programmable mRNA lipid nanoparticle (LNP) platform that orchestrates a division-of-labor immune response in vivo. By modulating the LNP nano-bio interface through 10% 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) doping and indirect IgG-based anti-CD5 tethering, we achieve selective and efficient transfection of endogenous splenic T cells. This platform simultaneously generates two complementary chimeric antigen receptor (CAR)-T populations: a vascular endothelial growth factor receptor 2 (VEGFR2)-directed subset that transiently remodels the tumor endothelium, and a tumor-antigen-directed subset that executes cytotoxic clearance. Mechanistic analyses reveal that focal endothelial disruption creates a permissive window for the infiltration, expansion, and activation of tumor-directed CAR-T cells. In refractory melanoma and colorectal carcinoma models in female mice, this dual-programming strategy achieves superior tumor control and drives tumor regression while reducing systemic toxicity. By bypassing ex vivo manufacturing, this approach provides a scalable and host-directed strategy to breach infiltrative barriers in solid-tumor immunotherapy.
Source: Nature Communications
Institutions: Chinese Academy of Sciences, National Center for Nanoscience and Technology, University of Chinese Academy of Sciences, Beihang University, Ministry of Industry and Information Technology, Harbin Institute of Technology, Second Hospital of Tianjin Medical University, Tianjin Medical University, Institute of Zoology, Chinese PLA General Hospital, Chinese People's Liberation Army, Capital Medical University, Beijing Chao-Yang Hospital, Capital Medical University, Army Medical University, Xinqiao Hospital
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W7236784172
